Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

BACKGROUND: Significant progress in treatment of metastatic castration resistant prostate cancer (mCRPC) has been made. Biomarkers to tailor therapy are scarce. To facilitate decision-making we evaluated dynamic changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and prostate specific...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Mikah, Phillip, Krabbe, Laura-Maria, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres-Jan, Boegemann, Martin
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4790058/
https://ncbi.nlm.nih.gov/pubmed/26975660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2260-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares